… the treatment of myelofibrosis. On January 7, the FDA and European Medicines Agency … anti-CDH17 antibody-drug conjugate, for the treatment of pancreatic cancer … FDA granted BTD for bezuclastinib in combination with sunitinib (Sutent) for the treatment …

… with sunitinib (Sutent) for the treatment of patients with … treatment options for nearly 2 decades. Recently, the FDA accepted a new drug … presented at a major medical conference during the … additional planned phase 2 trial will investigate bezuclastinib plus …

… .S. Food and Drug Administration (FDA) granted Breakthrough Therapy … The trial included patients who received prior treatment with Novartis … sunitinib under the brand Sutent. Bezuclastinib’s Efficacy Outshines … the PEAK trial at a major medical meeting during …

… a new drug application (NDA) for bezuclastinib plus sunitinib (Sutent) as treatment for … PEAK trial are going to be shared at a major medical conference … continued, close collaboration with the FDA as we advance bezuclastinib toward …

… of view” when educating doctors about zanzalintinib’s overall … mCRC. Instead, earlier treatment settings and expansions into … Opdivo against Pfizer’s Sutent in previously untreated patients … -stage pipeline includes antibody-drug conjugates targeting DLL3, 5T4 …

… modification of treatments, enhancement of treatment outcomes through personalised medicine, funding … pharmacy corporation, Amneal Pharmaceuticals Inc. This drug, which is … ) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient …

… to cabozantinib vs sunitinib [Sutent] and cabozantinib was superior … and the FDA approved having the clinical trial data added … seen in other trials. These were the treatment-related adverse events … sunitinib in first-line treatment of advanced renal cell …

… Kunz, professor of Internal Medicine (Medical Oncology) and director of … usually in pill form. Examples include everolimus, Sutent (sunitinib), and … several new FDA-approved treatments and clinical trials in their … is growing. We want doctors to be more aware …

… PEAK phase 3 trial evaluating bezuclastinib plus Sutent (sunitinib) … to submit a New Drug Application in 2026. … imatinib revolutionized first-line treatment, resistance inevitably develops, … combination may shift the treatment paradigm, offering patients not …

… GIST), treatment with bezuclastinib (CGT9486) in combination with Sutent (sunitinib … S. Food and Drug Administration (FDA) in the … PEAK trial compared bezuclastinib plus Sutent against Sutent alone … Sarcoma Medical Oncology, Division of Cancer Medicine, The …